177 related articles for article (PubMed ID: 36120106)
1. The subjective experience of heroin effects among individuals with chronic opioid use: Revisiting reinforcement in an exploratory study.
Martinez S; Brandt L; Comer SD; Levin FR; Jones JD
Addict Neurosci; 2022 Dec; 4():. PubMed ID: 36120106
[TBL] [Abstract][Full Text] [Related]
2. Modulation of drug choice by extended drug access and withdrawal in rhesus monkeys: Implications for negative reinforcement as a driver of addiction and target for medications development.
Negus SS; Banks ML
Pharmacol Biochem Behav; 2018 Jan; 164():32-39. PubMed ID: 28442370
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics of treatment-seeking prescription opioid vs. heroin-using adolescents with opioid use disorder.
Subramaniam GA; Stitzer MA
Drug Alcohol Depend; 2009 Apr; 101(1-2):13-9. PubMed ID: 19081205
[TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers.
Comer SD; Walker EA; Collins ED
Psychopharmacology (Berl); 2005 Oct; 181(4):664-75. PubMed ID: 16025322
[TBL] [Abstract][Full Text] [Related]
6. Comorbid chronic pain and opioid use disorder: literature review and potential treatment innovations.
Speed TJ; Parekh V; Coe W; Antoine D
Int Rev Psychiatry; 2018 Oct; 30(5):136-146. PubMed ID: 30398071
[TBL] [Abstract][Full Text] [Related]
7. A hidden aspect of the U.S. opioid crisis: Rise in first-time treatment admissions for older adults with opioid use disorder.
Huhn AS; Strain EC; Tompkins DA; Dunn KE
Drug Alcohol Depend; 2018 Dec; 193():142-147. PubMed ID: 30384321
[TBL] [Abstract][Full Text] [Related]
8. Opioid misuse viewed through person and place in the rural West.
Voss MW; Yaugher AC; Atismé K; Campbell A
J Opioid Manag; 2022; 18(2):151-159. PubMed ID: 35476884
[TBL] [Abstract][Full Text] [Related]
9. Use of methamphetamine and alcohol among people with opioid use disorder and HIV in Vietnam: a qualitative study.
Edsall A; Hoffman KA; Thuy DT; Mai PP; Hang NT; Khuyen TT; Trang NT; Kunkel LE; Giang LM; Korthuis PT
BMC Public Health; 2021 Sep; 21(1):1718. PubMed ID: 34548042
[TBL] [Abstract][Full Text] [Related]
10. Retrospectively assessed subjective effects of initial opioid use differ between opioid misusers with opioid use disorder (OUD) and those who never progressed to OUD: Data from a pilot and a replication sample.
Agrawal A; Jeffries PW; Srivastava AB; McCutcheon VV; Lynskey MT; Heath AC; Nelson EC
J Neurosci Res; 2022 Jan; 100(1):353-361. PubMed ID: 32468677
[TBL] [Abstract][Full Text] [Related]
11. Memantine produces modest reductions in heroin-induced subjective responses in human research volunteers.
Comer SD; Sullivan MA
Psychopharmacology (Berl); 2007 Aug; 193(2):235-45. PubMed ID: 17406858
[TBL] [Abstract][Full Text] [Related]
12. Extended-release naltrexone versus standard oral naltrexone versus placebo for opioid use disorder: the NEAT three-arm RCT.
Strang J; Kelleher M; Mayet S; Day E; Hellier J; Byford S; Murphy C; McLennan B; Shearer J; Ryan E; Marsden J
Health Technol Assess; 2019 Jan; 23(3):1-72. PubMed ID: 30702059
[TBL] [Abstract][Full Text] [Related]
13. Long-term antagonism of κ opioid receptors prevents escalation of and increased motivation for heroin intake.
Schlosburg JE; Whitfield TW; Park PE; Crawford EF; George O; Vendruscolo LF; Koob GF
J Neurosci; 2013 Dec; 33(49):19384-92. PubMed ID: 24305833
[TBL] [Abstract][Full Text] [Related]
14. Problematizing the DSM-5 criteria for opioid use disorder: A qualitative analysis.
Boyd S; Ivsins A; Murray D
Int J Drug Policy; 2020 Apr; 78():102690. PubMed ID: 32278265
[TBL] [Abstract][Full Text] [Related]
15. "It's way more than just writing a prescription": A qualitative study of preferences for integrated versus non-integrated treatment models among individuals with opioid use disorder.
Saunders EC; Moore SK; Walsh O; Metcalf SA; Budney AJ; Cavazos-Rehg P; Scherer E; Marsch LA
Addict Sci Clin Pract; 2021 Jan; 16(1):8. PubMed ID: 33499938
[TBL] [Abstract][Full Text] [Related]
16. Forging Neuroimaging Targets for Recovery in Opioid Use Disorder.
Stewart JL; May AC; Aupperle RL; Bodurka J
Front Psychiatry; 2019; 10():117. PubMed ID: 30899231
[TBL] [Abstract][Full Text] [Related]
17. Is South Africa being spared the global opioid crisis? A review of trends in drug treatment demand for heroin, nyaope and codeine-related medicines in South Africa (2012-2017).
Harker N; Lucas WC; Laubscher R; Dada S; Myers B; Parry CD
Int J Drug Policy; 2020 Sep; 83():102839. PubMed ID: 32650228
[TBL] [Abstract][Full Text] [Related]
18. Predictors of buprenorphine initial outpatient maintenance and dose taper response among non-treatment-seeking heroin dependent volunteers.
Woodcock EA; Lundahl LH; Greenwald MK
Drug Alcohol Depend; 2015 Jan; 146():89-96. PubMed ID: 25479914
[TBL] [Abstract][Full Text] [Related]
19. Modeling the Dynamics of Heroin and Illicit Opioid Use Disorder, Treatment, and Recovery.
Cole S; Wirkus S
Bull Math Biol; 2022 Mar; 84(4):48. PubMed ID: 35237877
[TBL] [Abstract][Full Text] [Related]
20. The effects of extended-release injectable naltrexone and incentives for opiate abstinence in heroin-dependent adults in a model therapeutic workplace: A randomized trial.
Jarvis BP; Holtyn AF; DeFulio A; Koffarnus MN; Leoutsakos JS; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
Drug Alcohol Depend; 2019 Apr; 197():220-227. PubMed ID: 30852374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
